Management

Dr. Forsell was the Executive Chairman of Obtech Medical AG, the team’s previous successful medical technology business which commercialized the SAGB, an adjustable gastric band to treat obesity that Dr. Forsell developed. The total gastric banding market peaked at 42% market share of all obesity surgery.  Dr. Forsell has gained extensive experience during this long journey how to lead and develop a business from inception to a successful global enterprise. Obtech was later sold for a significant amount to a leading healthcare company. As CEO of Implantica, he is focused on guiding Implantica to the next level.

Dr. Forsell is an internationally renowned surgeon and the brain behind Implantica’s decade of patent and development work focusing on how to move advanced technology into the body. He developed Implantica’s wireless energizing and eHealth platforms. He is the inventor and originator of most of Implantica’s products and the large patent portfolio of >1’000 patent cases. This includes RefluxStop™, a device obtaining CE mark after a very successful clinical trial and will cause a potential paradigm shift in the treatment of acid reflux. Dr. Forsell is a specialist in surgery at the Karolinska Hospital, and he obtained his medical degree at the Karolinska Institute in Stockholm, Sweden. He has also studied basic law, tax and finance.

Peter Forsell owns 21,616,770 SDRs and 1,125,000,000 class B shares in Implantica AG.

Mr. Öhrnberg has more than 15 years’ experience from senior finance and general management positions. Prior to joining Implantica in 2020, Mr. Öhrnberg served as CFO at Talkpool, a publicly listed technology group domiciled in Switzerland. Previously, Mr. Öhrnberg was Vice President Finance & Strategy at Swiss Re, a global Fortune 500 company. He also co-founded an online platform that was acquired by a public company. Mr. Öhrnberg received a M.Sc. Business Administration at Stockholm School of Economics; and a M.Sc. Computer and Systems Sciences at Stockholm University; holds an ACCA Diploma in International Financial Reporting; and is a Chartered Financial Analyst.

Andreas Öhrnberg has a 5-year share program of 87,169 SDRs.

Stephan Siegenthaler co-developed a gastric band (SAGB) business into a multinational company, which eventually commanded approximately 28 percent of the obesity surgery market outside of the US over a six-year period and was sold to Johnson & Johnson for a significant amount. He focused primarily on building the sales organization, created a large key surgical and hospital network, recruited high-performing sales people and established own sales force in 32 countries.

Mr. Siegenthaler has more than 20 years of industry experience focused on building a large network of key-opinion-leaders as the platform for a multinational sales expansion. Mr. Siegenthaler has been with Implantica since its founding, and was a Rector at the University Lucerne of Applied Sciences and Arts and has a degree in music.

Stephan Siegenthaler owns 900,000 SDRs in Implantica AG.

Nicole Pehrsson joined Implantica in 2016, responsible for Investor relations. Since then she has expanded her role focusing on strategic developments at the company, joining Executive management as VP Operations & IR. Nicole has strong financial experience in equity research and corporate finance, having worked as an equity research analyst at EFG Bank AG, Zurich, and before that as a business developer in the corporate finance team of JP Morgan. She worked as an analyst in corporate finance at Kidder, Peabody & Co. Inc. in Los Angeles and Boston where she focused primarily on healthcare and IT industries. She received a Bachelor of Arts in Economics from UCLA (summa cum laude).

Nicole Pehrsson owns 481, 417 SDRs in Implantica AG and has a share program in the Company for 42,400 shares vesting over a five year period.

Amit Kukreja has served in several worldwide and regional leadership and advisory roles, driving and shaping reimbursement, health economics, clinical evidence planning, payer relations, and upstream marketing & communications for disruptive MedTech products. Before joining Implantica in 2021, Amit served as Vice President of Corporate Market Access at Masimo Corporation, a global leader in innovative noninvasive patient monitoring technologies, responsible for global Market Access development strategy with a key focus on remote monitoring and telehealth technologies. Prior to that, he was the Vice President of Global Marketing, Reimbursement & Patient Access at Second Sight Medical Products, a global leader in neuromodulation implantable devices for blindness.

Susana Mogensen currently serves as a Vice President Quality and Regulatory Affairs at Implantica. She has over 17 years of quality, clinical and regulatory affairs experience in start up and mid-size companies with a successful track record of bringing multiple complex PMA products to the market. Most recently, Ms. Mogensen was responsible for a PMA approval of a novel cardiovascular implantable device. Prior to Implantica, she was Head of Quality, Clinical & Regulatory Affairs at Laborie Switzerland, a Global company with solutions in urology and gastroenterology where she integrated the Swiss QA & RA departments into the Global organization of Laborie. Ms. Mogensen is an expert in EU Medical Device Regulation, FDA regulations having been responsible for 510K, PMA and IDE approvals as well as CE marking certification of products under the MDR. Ms. Mogensen has a Ph.D. in Plant Biology from Brigham Young University and Master of Science degrees in Horticulture and Agriculture Engineering from the Instituto Superior de Agronomia and Brigham Young University.